Global Dry Eye Disease (DED) Market – Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid –19 Impact, Competition and Forecast (2021–2026)

Executive Summary

Global Dry Eye Disease Market, valued at USD 5378.59 Million in the year 2020, affects tens of millions of individuals around the world, and both its frequency and impact increase with age. Consequently, it is considered a major international health concern. Dry eye is the most commonly reported reason for seeking medical eye care, and up to one in five patients presenting to hospital outpatient clinics or optometry practices experience dry eye. With increased life expectancy, aging population, increasing number of working population, excess time spend using screens, and various lifestyle changes, the economic and social impacts of DED are expected to grow substantially in the coming years, which has been anticipated to infuse growth in the market for Dry Eye Disease during the forecast period of 2021-2026.

Under the Disease segment, Evaporative Dry Eye Disease are anticipated to witness the largest market share owing to recent clinical and epidemiological studies confirming that most dry eye patients show signs of mixed evaporative and aqueous deficient dry eye, with evaporative dry eye being the most common manifestation. Evaporative dry eye is most often associated with meibomian gland dysfunction (MGD) that will be pushing growth in the market for Dry Eye Disease during the coming years.

Hospitals, followed by Clinics attained substantial market share under End User segment, chiefly on the back of growing number of people suffering from eye disorders supported by manufacturers spending heavily on creating awareness among people regarding variety of eye disorders and their consequences, and investing in expanding their manufacturing capacity in order to cater to rising demand for eye care products, which will spur the market growth for dry eye care products in the coming years.

Among the regions, North America, followed by Europe and Asia Pacific, will experience remarkable market share owing to presence of various leading global manufacturers in the region with companies ramping up their production capacity with escalating number of people suffering from dry disease owing to excess time spent over screens supported by investment in expanding product portfolio by manufacturers to offer various types of Dry Eye Disease products to users. These factors will be accelerating the market growth during the forecast period.

Scope of the Report

• The report analyses Dry Eye Disease market By Value.
• The report analyses Dry Eye Disease Market By Disease (Aqueous, Evaporative, Others).
• The report assesses the Dry Eye Disease market By Treatment (Eye Drops, Anti-Inflammatory Drugs, Others).
• The report further segments the market By End User (Home Healthcare, Clinics, Hospitals, and Others) and By Distribution Channel (Hospital Pharmacies, Retailers, Online, Others).
• The Global Dry Eye Disease Market has been analysed By Region (North America, Europe, Asia Pacific) and By Country (United States, Canada, Germany, France, United Kingdom, Italy, China, Japan, India, South Korea).
• The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Technological Innovations, and Role of Manufacturers during Covid-19 pandemic.
• Also, the attractiveness of the market has been presented By Region, Disease, Treatment, End User, and Distribution Channel. Additionally, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
• The companies analysed in the report include Johnson & Johnson, Bausch Health, Alcon, Allergan PLC, Novartis AG, Santen Pharmaceuticals Co. Ltd, VISUfarma, Horus Pharma, Novaliq GmbH, Sentiss Pharma Pvt Ltd..
• The report presents the analysis of Dry Eye Disease market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Key Target Audience

• Dry Eye Disease Products Manufacturers
• Hospitals, Clinics, and Healthcare Units
• Pharmacies, and Retailers
• Consulting and Advisory Firms
• Investment Banks and Equity Firms

1. Report Scope and Methodology
1.1 Research Methodology
1.2 Executive Summary

2. Strategic Recommendations

3. Dry Eye Disease Market Product Outlook

4. Global Dry Eye Disease Market: Sizing and Forecast

5. Global Dry Eye Disease Market Segmentation By Disease, By Treatment, By End User, By Distribution Channel
5.1 Competitive Scenario of Global Dry Eye Disease Market: By Disease
5.1.1 Aqueous ñ Market Size and Forecast (2016-2026)
5.1.2 Evaporative ñ Market Size and Forecast (2016-2026)
5.1.3 Others ñ Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Dry Eye Disease Market: By Treatment
5.2.1 Eye Drops ñ Market Size and Forecast (2016-2026)
5.2.2 Anti-Inflammatory Drugs ñ Market Size and Forecast (2016-2026)
5.2.3 Others ñ Market Size and Forecast (2016-2026)
5.3 Competitive Scenario of Global Dry Eye Disease Market: By End User
5.3.1 Home Healthcare ñ Market Size and Forecast (2016-2026)
5.3.2 Clinics ñ Market Size and Forecast (2016-2026)
5.3.3 Hospitals ñ Market Size and Forecast (2016-2026)
5.3.4 Others ñ Market Size and Forecast (2016-2026)
5.4 Competitive Scenario of Global Dry Eye Disease Market: By Distribution Channel
5.4.1 Hospital Pharmacies ñ Market Size and Forecast (2016-2026)
5.4.2 Retailers ñ Market Size and Forecast (2016-2026)
5.4.3 Online ñ Market Size and Forecast (2016-2026)
5.4.4 Others ñ Market Size and Forecast (2016-2026)

6. Global Dry Eye Disease Market: Regional Analysis

7. North America Dry Eye Disease Market: Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value))
7.1 North America Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
7.2 North America Dry Eye Disease Market ñ Prominent Companies
7.3 Market Segmentation by Disease (Aqueous, Evaporative, and Others)
7.4 Market Segmentation by Treatment (Eye Drops, Anti-Inflammatory Drugs, and Others)
7.5 Market Segmentation by End User (Home Healthcare, Clinics, Hospitals, and Others)
7.6 Market Segmentation by Distribution Channel (Hospital Pharmacies, Retailers, Online, and Others)

7.7 North America Dry Eye Disease Market: Country Analysis
7.8 Market Opportunity Chart of North America Dry Eye Disease Market ñ By Country, By Value (Year 2026)
7.9 Competitive Scenario of North America ñ By Country
7.10 United States Dry Eye Disease Market: Size and Forecast (2021ñ2026), By Value
7.11 United States Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
7.12 Canada Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
7.13 Canada Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)

8. Europe Dry Eye Disease Market: Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value))
8.1 Europe Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
8.2 Europe Dry Eye Disease Market ñ Prominent Companies
8.3 Market Segmentation by Disease (Aqueous, Evaporative, Others)
8.4 Market Segmentation by Treatment (Eye Drops, Anti-Inflammatory Drugs, Others)
8.5 Market Segmentation by End User (Home Healthcare, Clinics, Hospitals, Others)
8.6 Market Segmentation by Distribution Channel (Hospital Pharmacies, Retailers, Online, and Others)

8.7 Europe Dry Eye Disease Market: Country Analysis
8.8 Market Opportunity Chart of Europe Dry Eye Disease Market - By Country, By Value (Year 2026)
8.9 Competitive Scenario of Europe ñ By Country
8.10 Germany Dry Eye Disease Market: Size and Forecast (2021ñ2026), By Value
8.11 Germany Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
8.12 France Dry Eye Disease Market: Size and Forecast (2021ñ2026), By Value
8.13 France Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026)(By Value)
8.14 United Kingdom Dry Eye Disease Market: Size and Forecast (2021ñ2026), By Value
8.15 United Kingdom Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
8.16 Italy Dry Eye Disease Market: Size and Forecast (2021ñ2026), By Value
8.17 Italy Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)

9. Asia Pacific Dry Eye Disease Market: Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021ñ2026) (By Value))
9.1 Asia Pacific Dry Eye Disease Market: Size and Forecast (2021ñ2026), By Value
9.2 Asia Pacific Dry Eye Disease Market ñ Prominent Companies
9.3 Market Segmentation by Disease (Aqueous, Evaporative, and Others)
9.4 Market Segmentation by Treatment (Eye Drops, Anti-Inflammatory Drugs, Others)
9.5 Market Segmentation by End User (Home Healthcare, Clinics, Hospitals, Others)
9.6 Market Segmentation by Distribution Channel (Hospital Pharmacies, Retailers, Online, and Others)

9.7 Asia Pacific Dry Eye Disease Market: Country Analysis
9.8 Market Opportunity Chart of Asia Pacific Dry Eye Disease Market ñ By Country, By Value (Year 2026)
9.9 Competitive Scenario of Asia Pacific By Country
9.10 China (Mainland China, Hong Kong, Macau, and Taiwan) Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
9.11 China (Mainland China, Hong Kong, Macau, and Taiwan) Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
9.12 Japan Dry Eye Disease Market: Size and Forecast (2021-2026) By Value
9.13 Japan (Mainland China, Hong Kong, Macau, and Taiwan) Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026)(By Value)
9.14 India Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
9.15 India Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026) (By Value)
9.16 South Korea Dry Eye Disease Market: Size and Forecast (2021-2026), By Value
9.17 South Korea Market Segmentation by Disease, By Treatment, By End User, and By Distribution Channel (2021-2026)(By Value)

10. Global Dry Eye Disease Market Dynamics
10.1 Global Dry Eye Disease Market Drivers
10.2 Global Dry Eye Disease Market Restraints
10.3 Global Dry Eye Disease Market Trends

11. Market Attractiveness and Strategic Analysis
11.1 Market Attractiveness
11.1.1 Market Attractiveness Chart of Global Dry Eye Disease Market - By Disease, By Value (Year 2026)
11.1.2 Market Attractiveness Chart of Global Dry Eye Disease Market - By Treatment, By Value (Year 2026)
11.1.3 Market Attractiveness Chart of Global Dry Eye Disease Market - By End User, By Value (Year 2026)
11.1.4 Market Attractiveness Chart of Global Dry Eye Disease Market - By Distribution Channel, By Value (Year 2026)
11.1.5 Market Attractiveness Chart of Global Dry Eye Disease Market - By Region, By Value (Year 2026)
11.2 Strategic Analysis
11.2.1 Latest Technological Innovations and Mergers & Acquisitions
11.2.2 Market Share Analysis

12. Company Profiles (Business Description, Financial Analysis, Business Strategy)
12.1 Johnson & Johnson
12.2 Bausch Health
12.3 Alcon
12.4 Allergan PLC
12.5 Novartis AG
12.6 Santen Pharmaceuticals Co. Ltd
12.7 VISUfarma
12.8 Horus Pharma
12.9 Novaliq GmbH
12.10 Sentiss Pharma Pvt Ltd


List Of Figures

Figure 1: Global Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 3: Global Prevalence of Glaucoma, 2015-2019 (In %)
Figure 4: Global Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 5: Global Prevalence of Cataract, 2015-2019 (In %)
Figure 6: Global Population, By End User Group, 2020 (In Millions)
Figure 7: Global Total Population, By End User 15ñ64 Years, 2015-2019 (In Billion)
Figure 8: Global Total Population, By End User 0ñ14 Years, 2015-2019 (In Billions)
Figure 9: Segmental Analysis, By Disease, 2020, 2026
Figure 10: Global Dry Eye Disease Market ñ By Aqueous, By Value (USD Million), 2016-2026
Figure 11: Global Dry Eye Disease Market ñ By Evaporative, By Value (USD Million), 2016-2026
Figure 12: Global Dry Eye Disease Market ñ By Others, By Value (USD Million), 2016-2026
Figure 13: Segment Analysis by Treatment, 2020, 2026
Figure 14: Global Dry Eye Disease Market ñ By Eye Drops, By Value (USD Million), 2016-2026
Figure 15: Global Dry Eye Disease Market ñ By Anti-Inflammatory Drugs, By Value (USD Million), 2016-2026
Figure 16: Global Dry Eye Disease Market ñ By Others, By Value (USD Million), 2016-2026
Figure 17: Segmental Analysis, By End User, 2020, 2026
Figure 18: Global Dry Eye Disease Market ñ By Home Healthcare, By Value (USD Million), 2016-2026
Figure 19: Global Dry Eye Disease Market ñ By Clinics, By Value (USD Million), 2016-2026
Figure 20: Global Dry Eye Disease Market ñ By Hospitals, By Value (USD Million), 2016-2026
Figure 21: Global Dry Eye Disease Market ñ By Others, By Value (USD Million), 2016-2026
Figure 22: Segment Analysis by Distribution Channel, 2020, 2026
Figure 23: Global Dry Eye Disease Market ñ By Hospital Pharmacies, By Value (USD Million), 2016-2026
Figure 24: Global Dry Eye Disease Market ñ By Retailers, By Value (USD Million), 2016-2026
Figure 25: Global Dry Eye Disease Market ñ By Online, By Value (USD Million), 2016-2026
Figure 26: Global Dry Eye Disease Market ñ By Others, By Value (USD Million), 2016-2026
Figure 27: Segment Analysis by Region, 2020, 2026
Figure 28: North America Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 29: North America Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 30: North America Prevalence of Glaucoma, 2015-2019 (In %)
Figure 31: North America Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 32: North America Prevalence of Cataract, 2015-2019 (In %)
Figure 33: North America Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 34: North America Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 35: North America Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 36: North America Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 37: Market Opportunity Chart of North America Dry Eye Disease Market ñ By Country, By Value, 2026
Figure 38: Segment Analysis by Country, 2020, 2026
Figure 39: United States Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 40: United States Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 41: United States Prevalence of Glaucoma, 2015-2019 (In %)
Figure 42: United States Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 43: United States Prevalence of Cataract, 2015-2019 (In %)
Figure 44: United States Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 45: United States Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 46: United States Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 47: United States Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 48: Canada Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 49: Canada Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 50: Canada Prevalence of Glaucoma, 2015-2019 (In %)
Figure 51: Canada Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 52: Canada Prevalence of Cataract, 2015-2019 (In %)
Figure 53: Canada Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 54: Canada Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 55: Canada Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 56: Canada Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 57: Europe Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 58: Europe Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 59: Europe Prevalence of Glaucoma, 2015-2019 (In %)
Figure 60: Europe Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 61: Europe Prevalence of Cataract, 2015-2019 (In %)
Figure 62: Europe Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 63: Europe Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 64: Europe Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 65: Europe Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 66: Market Opportunity Chart of Europe Dry Eye Disease Market ñ By Country, By Value, 2026
Figure 67: Europe Dry Eye Disease Market, By Country, 2020, 2026
Figure 68: Germany Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 69: Germany Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 70: Germany Prevalence of Glaucoma, 2015-2019 (In %)
Figure 71: Germany Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 72: Germany Prevalence of Cataract, 2015-2019 (In %)
Figure 73: Germany Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 74: Germany Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 75: Germany Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 76: Germany Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 77: France Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 78: France Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 79: France Prevalence of Glaucoma, 2015-2019 (In %)
Figure 80: France Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 81: France Prevalence of Cataract, 2015-2019 (In %)
Figure 82: France Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 83: France Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 84: France Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 85: France Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 86: United Kingdom Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 87: United Kingdom Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 88: United Kingdom Prevalence of Glaucoma, 2015-2019 (In %)
Figure 89: United Kingdom Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 90: United Kingdom Prevalence of Cataract, 2015-2019 (In %)
Figure 91: United Kingdom Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 92: United Kingdom Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 93: United Kingdom Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 94: United Kingdom Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 95: Italy Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 96: Italy Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 97: Italy Prevalence of Glaucoma, 2015-2019 (In %)
Figure 98: Italy Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 99: Italy Prevalence of Cataract, 2015-2019 (In %)
Figure 100: Italy Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 101: Italy Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 102: Italy Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 103: Italy Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 104: Asia Pacific Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 105: Asia Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 106: Asia Prevalence of Glaucoma, 2015-2019 (In %)
Figure 107: Asia Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 108: Asia Prevalence of Cataract, 2015-2019 (In %)
Figure 109: Asia Pacific Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 110: Asia Pacific Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 111: Asia Pacific Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 112: Asia Pacific Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 113: Market Opportunity Chart of Asia Pacific Dry Eye Disease Market By Country, By Value, 2026
Figure 114: Asia Pacific Dry Eye Disease Market, By Country, 2020, 2026
Figure 115: China Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 116: China Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 117: China Prevalence of Glaucoma, 2015-2019 (In %)
Figure 118: China Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 119: China Prevalence of Cataract, 2015-2019 (In %)
Figure 120: China Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 121: China Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 122: China Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 123: China Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 124: Japan Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 125: Japan Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 126: Japan Prevalence of Glaucoma, 2015-2019 (In %)
Figure 127: Japan Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 128: Japan Prevalence of Cataract, 2015-2019 (In %)
Figure 129: Japan Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 130: Japan Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 131: Japan Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 132: Japan Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 133: India Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 134: India Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 135: India Prevalence of Glaucoma, 2015-2019 (In %)
Figure 136: India Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 137: India Prevalence of Cataract, 2015-2019 (In %)
Figure 138: India Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 139: India Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 140: India Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 141: India Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 142: South Korea Dry Eye Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 143: South Korea Prevalence of Blindness and Vision Loss, 2015-2019 (In %)
Figure 144: South Korea Prevalence of Glaucoma, 2015-2019 (In %)
Figure 145: South Korea Prevalence of Refraction Disorders, 2015-2019 (In %)
Figure 146: South Korea Prevalence of Cataract, 2015-2019 (In %)
Figure 147: South Korea Dry Eye Disease Market, By Disease, By Value, 2016-2026 (USD Million)
Figure 148: South Korea Dry Eye Disease Market, By Treatment, By Value, 2016-2026 (USD Million)
Figure 149: South Korea Dry Eye Disease Market, By End User, By Value, 2016-2026 (USD Million)
Figure 150: South Korea Dry Eye Disease Market, By Distribution Channel, By Value, 2016-2026 (USD Million)
Figure 151: Market Attractiveness Chart of Global Dry Eye Disease Market ñ By Disease, 2026
Figure 152: Market Attractiveness Chart of Global Dry Eye Disease Market By Treatment, 2026
Figure 153: Market Attractiveness Chart of Global Dry Eye Disease Market By End User, 2026
Figure 154: Market Attractiveness Chart of Global Dry Eye Disease Market By Distribution Channel, 2026
Figure 155: Market Attractiveness Chart of Global Dry Eye Disease Market By Region, 2026
Figure 156: Market Share of Leading Global Dry Eye Disease Companies, 2020 (In %)
Figure 157: Johnson & Johnson Revenue, 2015-2019 (In USD Billion)
Figure 158: Johnson & Johnson Net Revenue, By Business Segment, 2018 (In %)
Figure 159: Johnson & Johnson Net Revenue, By Business Segment, 2019 (In %)
Figure 160: Johnson & Johnson Net Revenue, By Geographic Segment, 2018 (In %)
Figure 161: Johnson & Johnson Net Revenue, By Geographic Segment, 2019 (In %)
Figure 162: Johnson & Johnson, Net Sales, By Medical Devices, 2018 (In %)
Figure 163: Johnson & Johnson, Net Sales, By Vision Segment, 2018 (In %)
Figure 164: Bausch Health Revenue, 2015-2019 (In USD Billion)
Figure 165: Bausch Health Net Revenue, By Business Segment, 2018 (In %)
Figure 166: Bausch Health Net Revenue, By Business Segment, 2019 (In %)
Figure 167: Bausch Health Net Revenue, By Geographic Segment, 2018 (In %)
Figure 168: Bausch Health Net Revenue, By Geographic Segment, 2019 (In %)
Figure 169: Alcon Revenue, 2015-2019 (In USD Billion)
Figure 170: Alcon Net Revenue, By Business Segment, 2018 (In %)
Figure 171: Alcon Net Revenue, By Business Segment, 2019 (In %)
Figure 172: Alcon Revenue, Business Segment, 2018, 2019 (In USD Billion)
Figure 173: Alcon Net Revenue, By Geographic Segment, 2018 (In %)
Figure 174: Alcon Net Revenue, By Geographic Segment, 2019 (In %)
Figure 175: Allergan PLC Revenue, 2014-2018 (In USD Billion)
Figure 176: Allergan PLC Net Revenue, By Business Segment, 2017 (In %)
Figure 177: Allergan PLC Net Revenue, By Business Segment, 2018 (In %)
Figure 178: Allergan PLC Net Revenue, By Geographic Segment, 2017 (In %)
Figure 179: Allergan PLC Net Revenue, By Geographic Segment, 2018 (In %)
Figure 180: Novartis AG Revenue, 2015-2019 (In USD Billion)
Figure 181: Novartis AG Net Revenue, By Business Segment, 2018 (In %)
Figure 182: Novartis AG Net Revenue, By Business Segment, 2019 (In %)
Figure 183: Santen Pharmaceutical Co. Ltd. Revenue, 2015-2019 (In USD Billion)
Figure 184: Santen Pharmaceutical Co. Ltd. Revenue, By Business Segment, 2018 (In %)
Figure 185: Santen Pharmaceutical Co. Ltd. Revenue, By Business Segment, 2019 (In %)
Figure 186: Santen Pharmaceutical Co. Ltd. Net Revenue, By Geographic Segment, 2018 (In %)
Figure 187: Santen Pharmaceutical Co. Ltd. Net Revenue, By Geographic Segment, 2019 (In %)
Companies Mentioned
Johnson & Johnson, Bausch Health, Alcon, Allergan PLC, Novartis AG, Santen Pharmaceuticals Co. Ltd, VISUfarma, Horus Pharma, Novaliq GmbH, Sentiss Pharma Pvt Ltd.


Global Biopsy Devices Market 2023

DescriptionBiopsies are an important medical procedure where doctors extract cells or tissues from a patients body in order to examine them under a microscope. This closer inspection of samples provides

USD 3650 View Report

Global Veterinary Dermatology Drugs Market 2023

DescriptionThe global veterinary dermatology drugs market exhibits positive growth prospects, forecast to expand at a CAGR of 5.4% between 2023 and 2029 to reach USD 8.08 billion in value. Veterinary

USD 2025 View Report

Global Dry X-Ray Film Market 2023

Dry X-Ray film is cost-effective and environmentally friendly as it eliminates the need for chemical disposal. It possesses features such as outstanding grayscale and contrast, high resolution, and high density,

USD 2850 View Report

Moderate and Severe Dry Eye Disease Market in China 2023

Dry eye disease is a common eye condition that occurs when the eyes do not produce enough tears or the tears evaporate too quickly. It can cause discomfort, irritation, and

USD 675 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available